Applied DNA Sciences (APDN) stock fumbled in the after-market as in its Q4 financial report announced, the company reported a loss and missed revenue estimates.
The company lost $0.82 per share in its most recent quarter, compared with a $0.59 per share in the previous quarter. This compares to a loss of $1.44 per share last year, adjusted for non-recurring items.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
- Are You Looking for Dividend Paying Stocks? Here are the Best Buys in 2021
- Two Promising Pet Stocks for Investment as we Head 2021
The last quarter report represents an earnings surprise of -38.98%. A quarter ago, this DNA-based security technology company was expected to post a loss of $0.62 per share – however, it recorded a loss of $0.72, a surprise of -16.13%.
It hasn’t been able to surpass consensus EPS estimates over the last four quarters.
For the quarter ended September 2020, Applied DNA Sciences posted $0.31 million revenues, missing the Zacks Consensus Estimate by 55.14%. Revenues last year were $1.70 million. Over the last four quarters, the company has failed to surpass consensus revenue estimates.
Future earnings projections and management’s commentary during the earnings call will largely determine whether the stock’s immediate positive price movement can be sustained.
The shares of Applied DNA Sciences (APDN) have gained about 39.6% since the beginning of this year compared with the S&P 500’s gain of 14.6%.
